195 related articles for article (PubMed ID: 31407032)
21. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
Houvenaeghel G; Sabatier R; Reyal F; Classe JM; Giard S; Charitansky H; Rouzier R; Faure C; Garbay JR; Daraï E; Hudry D; Gimbergues P; Villet R; Lambaudie E
Br J Cancer; 2016 Oct; 115(9):1024-1031. PubMed ID: 27685443
[TBL] [Abstract][Full Text] [Related]
22. Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
Sugianto J; Sarode V; Peng Y
Hum Pathol; 2014 Apr; 45(4):802-9. PubMed ID: 24560018
[TBL] [Abstract][Full Text] [Related]
23. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
25. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
26. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
[TBL] [Abstract][Full Text] [Related]
27. Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers.
Rao D; Kimler BF; Nothnick WB; Davis MK; Fan F; Tawfik O
Hum Pathol; 2015 Jun; 46(6):876-83. PubMed ID: 25841305
[TBL] [Abstract][Full Text] [Related]
28. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
30. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.
Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D
Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640
[TBL] [Abstract][Full Text] [Related]
31. Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients).
Eltohamy MI; Badawy OM; El kinaai N; Loay I; Nassar HR; Allam RM; Sakr MA
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3581-3589. PubMed ID: 30583686
[TBL] [Abstract][Full Text] [Related]
32. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.
Munzone E; Botteri E; Sciandivasci A; Curigliano G; Nolè F; Mastropasqua M; Rotmensz N; Colleoni M; Esposito A; Adamoli L; Luini A; Goldhirsch A; Viale G
Breast Cancer Res Treat; 2012 Jul; 134(1):277-82. PubMed ID: 22467243
[TBL] [Abstract][Full Text] [Related]
35. Outcome of pN0 Triple-Negative Breast Cancer with or without Lymph Node Irradiation: A Single Institution Experience.
Khalifa J; Duprez-Paumier R; Filleron T; Lacroix Triki M; Jouve E; Dalenc F; Massabeau C
Breast J; 2016 Sep; 22(5):510-9. PubMed ID: 27261365
[TBL] [Abstract][Full Text] [Related]
36. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
37. Expression of ROR1 has prognostic significance in triple negative breast cancer.
Chien HP; Ueng SH; Chen SC; Chang YS; Lin YC; Lo YF; Chang HK; Chuang WY; Huang YT; Cheung YC; Shen SC; Hsueh C
Virchows Arch; 2016 May; 468(5):589-95. PubMed ID: 26874851
[TBL] [Abstract][Full Text] [Related]
38. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Pedersen MH; Hood BL; Ehmsen S; Beck HC; Conrads TP; Bak M; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2019 Feb; 144(3):631-640. PubMed ID: 30110125
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
Yang Y; Wang Y; Deng H; Tan C; Li Q; He Z; Wei W; Zhou E; Liu Q; Liu J
BMC Cancer; 2019 Jun; 19(1):541. PubMed ID: 31170946
[TBL] [Abstract][Full Text] [Related]
40. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]